A new drug of Zizhu pharmaceutical, mifepristone tablet (10mg), completed a multicenter clinical study

It is understood that hysteromyoma is the most common benign tumor of female genitalia, which is common in women between 30 and 50 years old According to the health statistics yearbook of 2013, in China, the number of discharged patients due to uterine fibroids in 2012 was 2.7 times that of patients with endometriosis, and uterine fibroids have become the first disease of gynecological surgery in China However, the incidence rate of uterine fibroids in women of childbearing age is 20-25%, most of the myomas are asymptomatic, and often found in physical examination Only about 10% of them are symptomatic myoma It is necessary for treatment Even so, about 3 million 800 thousand of patients with uterine fibroids need treatment Among them, the patients whose myoma size is less than 5cm, asymptomatic or asymptomatic, and near menopause can take expectant therapy Therefore, since its establishment in 1969, China Resources Zizhu Pharmaceutical Co., Ltd has continuously carried out cooperation in production, education and research relying on Beijing Technology Center for certified enterprises and Beijing Research Center for reproductive contraceptive engineering technology In 2014, a new drug mifepristone tablet (10mg) was successfully approved for preoperative treatment of uterine leiomyoma due to its high cost performance and clear effect It is reported that mifepristone is a typical progesterone receptor modulator, which can reduce the volume of uterine leiomyoma and improve the clinical symptoms by antagonizing progesterone or interfering with estrogen Its curative effect is exact, side effect is slight, oral administration is simple and convenient, which is of great significance to promote the progress of the treatment of hysteromyoma In the development of Zizhu pharmaceutical industry for more than 40 years, through continuous development and innovation, its first research and marketing of new products has filled many gaps in China's pharmaceutical market For example, in 1992, mifepristone was put on the market, which filled in the blank of drug abortion in China; in 1998, Yuting, the first emergency contraceptive drug in China, was put on the market, which reduced the occurrence of a large number of unwanted pregnancies In 2005, jinyuting, a levonorgestrel tablet, was put on the market, which was the second innovation of Yuting's products It was more convenient to take two tablets one by one, so as to avoid the drug failure caused by drug leakage; 2009 In 2013, levonorgestrel passed the EU cos certification and obtained the CEP certificate, meeting the international high-end technical standards; in 2010, it developed a multi vitamin and multi mineral tablet, which provided pregnant women with a series of products for the early, middle and late stages of pregnancy; in 2013, levonorgestrel passed the EU cos certification and obtained the CEP certificate with levonorgestrel in the same year, which was pre funded by the World Health Organization Quality certification Meanwhile, Cr Zizhu has been committed to internationalization since 2003 At present, there are 13 kinds of APIs and preparations, including mifepristone, levonorgestrel, ethinylestradiol, tibolone APIs, compound levonorgestrel tablets, Yuting, jinyuting, mifepristone tablets 25mg, mifepristone tablets 200mg, misoprostol tablets 3, misoprostol tablets 4, yueketing and Latan eye drops, which have obtained registration certificates in 19 countries, regions and international organizations.